Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03400956 · ClinicalTrials.gov registry record · Phase 3
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
A Phase 3 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT03400956 is a Phase 3 study that was terminated before completion, run by Bayer. The registered enrollment target is 103 participants.
The verdict
NCT03400956, a Phase 3 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
The primary objective of this study was to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo The secondary objectives of this study were to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids
Interventions
- DRUG Placebo
- DRUG Vilaprisan (BAY1002670)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03400956
The ClinicalTrials.gov registry entry for NCT03400956 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03400956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03400956 about?
NCT03400956 is a clinical study titled "Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)". The primary objective of this study was to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo The secondary objectives of this study were to additionally evaluate the efficacy and safety of vilaprisan in subjects w...
What is the current status of trial NCT03400956?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2018-01-24. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03400956?
The interventions under investigation include: Placebo (DRUG), Vilaprisan (BAY1002670) (DRUG).
Who is sponsoring clinical trial NCT03400956?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.